Effects of an Intervention With EVOO and Physical Activity in Patients With Systemic Lupus Erythematosus
EFINUTRILES
Effects of a Nutricional Intervention With EVOO Oil and Physical Activity in Patients With Systemic Lupus Erythematosus: Effect on Clinical Course, Epigenetic and Microbiome
1 other identifier
interventional
90
1 country
1
Brief Summary
In addition to the different pharmacological therapies available for the treatment of Systemic Lupus Erythematosus (SLE) as well as for its numerous associated complications (cutaneous, articular, hematological, neuropsychiatric, renal...), it has recently been proposed that 'health-related lifestyles' could have a determining role in balancing numerous organic processes at all levels. In line with this, the benefits of following a healthy dietary pattern such as the Mediterranean Diet and, specifically, the intake of Extra Virgin Olive Oil (EVOO) as well as the realization of regular physical exercise (PE) have been examined in numerous chronic non-communicable diseases such as obesity or cancer. However, in patients with autoimmune diseases, such as SLE, the possible effects of this synergy has not been investigated to date. Having demonstrated both the protective effect of a healthy dietary pattern and that of regular PE on the progression and risks associated with SLE in cross-sectional studies, non-intervention research has been developed that combines both strategies simultaneously, with nutritional supplementation or PE occurring independently. It is hypothesized that supplementation with EVOO in these patients together with PE will produce superior benefits compared to EVOO supplementation alone, showing changes in the phenotype of SLE and other parameters such as levels of chronicity/gravity, biomarkers (oxidative stress, immunological, inflammation), cardiovascular status and body composition.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 3, 2021
CompletedFirst Submitted
Initial submission to the registry
February 8, 2022
CompletedFirst Posted
Study publicly available on registry
March 2, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2023
CompletedDecember 20, 2022
December 1, 2022
1.2 years
February 8, 2022
December 19, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
SLE-specific index that assess disease activity through a combination of data from clinical records, physical examination, organ-specific functional tests and serological studies.
Participants will be followed over 24 weeks.
Secondary Outcomes (45)
Cumulative manifestations
Participants will be followed over 24 weeks.
SLICC/ACR (Systemic Lupus International Collaborating clinics/American College of Rheumatology) Damage Index for Systemic Lupus Erythematosus.
Participants will be followed over 24 weeks.
Pharmacological prescription
Participants will be followed over 24 weeks.
Glucose level
Participants will be followed over 24 weeks.
Urea level
Participants will be followed over 24 weeks.
- +40 more secondary outcomes
Study Arms (3)
Control Group
NO INTERVENTIONControl Group with 30 patients diagnosed with SLE following their normal lifestyle in terms of dietary intake and physical exercise.
Oil Group
EXPERIMENTALGroup with 30 patients diagnosed with SLE that add to their normal dietary intake a supplementation with 40ml of EVOO daily during 24 weeks, without changing their lifestyle in terms of physical exercise.
Oil + Exercise Group
EXPERIMENTALGroup with 30 patients diagnosed with SLE that besides adding to their normal dietary intake a supplementation with 40ml of EVOO daily during 24 weeks, will follow a physical exercise multimodal program the 12 last weeks.
Interventions
Daily intake of 40ml EVOO added to the normal intake of EVOO of the participants.
Besides the EVOO supplementation in the same conditions as the 'Intervention 1 Group', participants will add the follow-up of a Multimodal Physical Exercise (MFE) program during the remaining 12 weeks of intervention, 3 days per week, online and face-to-face group sessions on non-consecutive days. Continuous and intervalic cardiovascular exercise at moderate-intense intensity, controlled by the HR in reserve, with a duration of 15-45 minutes, also including sympathetic modulation exercises (stretching, breathing and meditation) and methods to promote recovery, with a duration of 10-30 minutes.
Eligibility Criteria
You may qualify if:
- Medium (8 to 11 points) to high (12 to 14 points) level of adherence to DM as measured by the 14-point DM adherence scale of the PREDIMED study.
- Sedentary, inactive or non-performing subjects of structured PE (+5h sitting or doing less than 300min of weekly physical activity or \<60min structured exercise per week).
You may not qualify if:
- Terminal stages of the disease
- Serum creatinine levels ≥1.5mg / dl
- Type 1 Diabetes Mellitus
- Infection, trauma or surgery six months prior to intervention
- SLICC\> 5
- Pregnant, with intention, or breastfeeding
- Diagnosis of other autoimmune / inflammatory diseases
- Participation in other PE guided programs
- Contraindication for PE: psychiatric or cognitive disorders, acute or chronic conditions (advanced lung disease, high requirements, stenosis\> 70%)
- BMI of morbid obesity (≥40)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Universidad de Granada
Granada, Granada, Spain, 18016, Spain
Related Publications (2)
Pocovi-Gerardino G, Correa-Rodriguez M, Callejas-Rubio JL, Rios-Fernandez R, Martin-Amada M, Cruz-Caparros MG, Rueda-Medina B, Ortego-Centeno N. Beneficial effect of Mediterranean diet on disease activity and cardiovascular risk in systemic lupus erythematosus patients: a cross-sectional study. Rheumatology (Oxford). 2021 Jan 5;60(1):160-169. doi: 10.1093/rheumatology/keaa210.
PMID: 32594173BACKGROUNDGil-Gutierrez R, Medina-Martinez I, Quesada-Caballero M, de la Hera-Fernandez FJ, Zamora-Pasadas M, Cantarero-Villanueva I, Albendin-Garcia L, Parola V, Rueda-Medina B, Correa-Rodriguez M. EFINUTRILES Study: Integrative Extra Virgin Olive Oil and Multimodal Lifestyle Interventions for Cardiovascular Health and SLE Management. Nutrients. 2025 Mar 19;17(6):1076. doi: 10.3390/nu17061076.
PMID: 40292522DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
María Correa Rodríguez, Professor
Universidad de Granada
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Participants randomly assigned in a 1:1:1 ratio to each of the three groups established through a centralized method with computer support (OxMaR software).
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
February 8, 2022
First Posted
March 2, 2022
Study Start
November 3, 2021
Primary Completion
December 30, 2022
Study Completion
June 30, 2023
Last Updated
December 20, 2022
Record last verified: 2022-12
Data Sharing
- IPD Sharing
- Will not share